bioRxivPharmacology & Toxicology
In silico, In vitro Screening of Plant Extracts for Anti-SARS-CoV-2 Activity and Evaluation of Their Acute and Sub-Acute Toxicity
Abstract
BackgroundIn the absence of a specific drug for COVID 19, treatment with plant extracts could be an option worthy of further investigation. PurposeTo screen the phytochemicals for Anti-SARS-CoV-2 in silico and evaluate their safety and efficacy in vitro and in vivo. MethodThe phytochemicals for Anti-SARS-CoV-2 were screened in silico using molecular docking. The hits generated from in silico screening were subjected for extraction, isolation and purification. The anti-SARS-CoV-2 activity of plant extracts of Z. piperitum (ATRI-CoV-E1), W. somnifera (ATRI-CoV-E2), C. inophyllum (ATRI-CoV-E3), A. paniculata (ATRI-CoV-E4), and C. Asiatica (ATRI-CoV-E5). The in vitro safety and anti-SARS-CoV-2 activity of plant extracts were performed in VeroE6 cells using Remdesivir as positive control. The acute and sub-acute toxicity study was performed in Wistar male and female rats. ResultsThe percentage of cell viability for ATRI-COV-E4, ATRI-COV-E5 and ATRI-COV-E2 treated VeroE6 cells were remarkably good on the 24th and 48th hour of treatment. The in vitro anti-SARS-CoV-2 activity of ATRI-COV-E4, ATRI-COV-E5 and ATRI-COV-E2 were significant for both E gene and N gene. The percentage of SARS-CoV-2 inhibition for ATRI-COV-E4 was better than Remdesivir. For E gene and N gene, Remdesivir showed IC50 of 0.15 {micro}M and 0.11 {micro}M respectively, For E gene and N gene, ATRI-CoV-E4 showed IC50 of 1.18 {micro}g and 1.16 {micro}g respectively. Taking the clue from in vitro findings, the plant extracts A. paniculata (ATRI-COV-E4), W. somnifera extract (ATRI-COV-E5) and C. asiatica extract (ATRI-COV-E2) were combined (ATRICOV 452) and evaluated for acute and sub-acute toxicity in Wistar male and female rats. No statistically significant difference in haematological, biochemical and histopathological parameters were noticed. ConclusionThe study demonstrated the Anti-SARS-CoV-2 activity in vitro and safety of plant extracts in both in vitro and in vivo experimental conditions.
- organism: human
- assay: proteomics
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- In vitro efficacy of Artemisia extracts against SARS-CoV-2
C. Nie, J. Trimpert, … P. H. Seeberger·bioRxiv·Feb 14, 2021
- The Petasites hybridus CO2-extract (Ze 339) blocks SARS-CoV-2 replication in vitro
L. Urda, M. Kreuter, … T. Klimkait·bioRxiv·Dec 3, 2021
- In vitro efficacy of Artemisinin-based treatments against SARS-CoV-2
K. Gilmore, Y. Zhou, … P. H. Seeberger·bioRxiv·Oct 5, 2020
- Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants
M. S. Nair, Y. Huang, … P. Weathers·bioRxiv·Jan 8, 2021
- Anti-SARS-CoV-2 activity of Andrographis paniculata extract and its major component Andrographolide in human lung epithelial cells and cytotoxicity evaluation in major organ cell representatives
K. Sa-ngiamsuntorn, A. Suksatu, … S. Hongeng·bioRxiv·Dec 8, 2020
- Development and optimisation of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: evaluation of 5676 phase 1 passed structures
W. Chiu, L. Verschueren, … E. Van Damme·bioRxiv·Feb 2, 2022